Vapotherm Competitors

Inovio Pharmaceuticals (NASDAQ:INO) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Volatility and Risk

Inovio Pharmaceuticals has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Vapotherm has a beta of -1.5, indicating that its share price is 250% less volatile than the S&P 500.

Earnings and Valuation

This table compares Inovio Pharmaceuticals and Vapotherm's top-line revenue, earnings per share and valuation.

Vapotherm has higher revenue and earnings than Inovio Pharmaceuticals. Vapotherm is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Inovio Pharmaceuticals and Vapotherm, as reported by MarketBeat.com.

Inovio Pharmaceuticals presently has a consensus price target of $17.00, suggesting a potential upside of 87.22%. Vapotherm has a consensus price target of $43.00, suggesting a potential upside of 89.01%. Given Vapotherm's stronger consensus rating and higher probable upside, analysts clearly believe Vapotherm is more favorable than Inovio Pharmaceuticals.

Profitability

This table compares Inovio Pharmaceuticals and Vapotherm's net margins, return on equity and return on assets.

Insider and Institutional Ownership

36.0% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.4% of Vapotherm shares are owned by institutional investors. 4.0% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 34.4% of Vapotherm shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Vapotherm beats Inovio Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

GenMark Diagnostics (NASDAQ:GNMK) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares GenMark Diagnostics and Vapotherm's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for GenMark Diagnostics and Vapotherm, as provided by MarketBeat.

GenMark Diagnostics presently has a consensus price target of $22.0125, suggesting a potential downside of 8.24%. Vapotherm has a consensus price target of $43.00, suggesting a potential upside of 89.01%. Given Vapotherm's stronger consensus rating and higher probable upside, analysts clearly believe Vapotherm is more favorable than GenMark Diagnostics.

Earnings & Valuation

This table compares GenMark Diagnostics and Vapotherm's top-line revenue, earnings per share and valuation.

GenMark Diagnostics has higher revenue and earnings than Vapotherm. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

96.9% of GenMark Diagnostics shares are held by institutional investors. Comparatively, 70.4% of Vapotherm shares are held by institutional investors. 3.3% of GenMark Diagnostics shares are held by insiders. Comparatively, 34.4% of Vapotherm shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

GenMark Diagnostics has a beta of 3.02, suggesting that its share price is 202% more volatile than the S&P 500. Comparatively, Vapotherm has a beta of -1.5, suggesting that its share price is 250% less volatile than the S&P 500.

Summary

GenMark Diagnostics beats Vapotherm on 9 of the 14 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares Luminex and Vapotherm's top-line revenue, earnings per share (EPS) and valuation.

Luminex has higher revenue and earnings than Vapotherm. Luminex is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Luminex and Vapotherm's net margins, return on equity and return on assets.

Volatility and Risk

Luminex has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Vapotherm has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500.

Institutional and Insider Ownership

88.1% of Luminex shares are held by institutional investors. Comparatively, 70.4% of Vapotherm shares are held by institutional investors. 9.4% of Luminex shares are held by insiders. Comparatively, 34.4% of Vapotherm shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Luminex and Vapotherm, as provided by MarketBeat.

Luminex presently has a consensus price target of $37.00, suggesting a potential upside of 0.38%. Vapotherm has a consensus price target of $43.00, suggesting a potential upside of 89.01%. Given Vapotherm's stronger consensus rating and higher probable upside, analysts clearly believe Vapotherm is more favorable than Luminex.

Summary

Luminex beats Vapotherm on 9 of the 14 factors compared between the two stocks.

Vapotherm (NYSE:VAPO) and Silk Road Medical (NASDAQ:SILK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Institutional and Insider Ownership

70.4% of Vapotherm shares are owned by institutional investors. 34.4% of Vapotherm shares are owned by insiders. Comparatively, 7.8% of Silk Road Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Vapotherm has a beta of -1.5, meaning that its stock price is 250% less volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Earnings & Valuation

This table compares Vapotherm and Silk Road Medical's top-line revenue, earnings per share and valuation.

Vapotherm has higher earnings, but lower revenue than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vapotherm and Silk Road Medical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and price targets for Vapotherm and Silk Road Medical, as reported by MarketBeat.

Vapotherm currently has a consensus price target of $43.00, indicating a potential upside of 89.01%. Silk Road Medical has a consensus price target of $61.75, indicating a potential upside of 20.32%. Given Vapotherm's stronger consensus rating and higher possible upside, analysts clearly believe Vapotherm is more favorable than Silk Road Medical.

Summary

Vapotherm beats Silk Road Medical on 8 of the 14 factors compared between the two stocks.

Vapotherm (NYSE:VAPO) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Valuation & Earnings

This table compares Vapotherm and Alphatec's revenue, earnings per share and valuation.

Vapotherm has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vapotherm and Alphatec's net margins, return on equity and return on assets.

Volatility and Risk

Vapotherm has a beta of -1.5, suggesting that its stock price is 250% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Vapotherm and Alphatec, as provided by MarketBeat.

Vapotherm presently has a consensus price target of $43.00, indicating a potential upside of 89.01%. Alphatec has a consensus price target of $15.4286, indicating a potential downside of 10.04%. Given Vapotherm's higher probable upside, research analysts plainly believe Vapotherm is more favorable than Alphatec.

Insider & Institutional Ownership

70.4% of Vapotherm shares are held by institutional investors. Comparatively, 31.8% of Alphatec shares are held by institutional investors. 34.4% of Vapotherm shares are held by insiders. Comparatively, 28.2% of Alphatec shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Vapotherm beats Alphatec on 8 of the 13 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Earnings and Valuation

This table compares Pulmonx and Vapotherm's gross revenue, earnings per share (EPS) and valuation.

Pulmonx has higher earnings, but lower revenue than Vapotherm.

Institutional & Insider Ownership

70.4% of Vapotherm shares are held by institutional investors. 34.4% of Vapotherm shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pulmonx and Vapotherm's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Pulmonx and Vapotherm, as provided by MarketBeat.

Pulmonx presently has a consensus price target of $58.00, suggesting a potential upside of 32.12%. Vapotherm has a consensus price target of $43.00, suggesting a potential upside of 89.01%. Given Vapotherm's stronger consensus rating and higher probable upside, analysts plainly believe Vapotherm is more favorable than Pulmonx.

Summary

Pulmonx beats Vapotherm on 6 of the 11 factors compared between the two stocks.